Education
About Us
Working with TipRanks
Follow Us
Danaher Corp. (DHR)
NYSE:DHR
DHR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$196.80 - $281.70
Previous CloseN/A
Volume816.38K
Average Volume (3M)4.84M
Market Cap
$151.80B
Enterprise Value$182.23B
Total Cash (Recent Filing)$2.08B
Total Debt (Recent Filing)$16.00B
Price to Earnings (P/E)40.2
Beta0.76
Next Earnings
Apr 22, 2025EPS Estimate
1.62Next Dividend Ex-Date
Mar 28, 2025Dividend Yield0.51%
Share Statistics
EPS (TTM)5.29
Shares Outstanding714,709,840
10 Day Avg. Volume3,682,954
30 Day Avg. Volume4,843,718
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.33
Price to Cash Flow (P/CF)18.70
P/FCF Ratio18.70
Enterprise Value/Market Cap1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.83
Enterprise Value/Ebitda26.99
Forecast
1Y Price Target
$264.50Price Target Upside25.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Biotech Segment RecoveryThe Biotech segment is viewed as driving a recovery in the shares over the next 12 months, fully offsetting pressure in China and minimal exposure to the Academic & Government segment.
Cost ManagementInitial cost savings announced in their recent 10-K are seen as providing the self-help needed to protect and potentially expand margins in the ‘25/’26 period.
Stock ValuationThe '25 EV/EBITDA multiple has de-rated 3 turns from peak levels offering a more attractive entry point into a stock seen as a long-term compounder undergoing short-term/cyclical issues.
Bears Say
Growth Estimate ConcernsConsensus organic growth estimates for the Biotech segment came down -42%, which was the largest concern for the name as expectations were misaligned with the pace of recovery modeled in that segment.
GuidanceThe '25 guide was underwhelming.
UnderperformanceDHR has underperformed the S&P 500 and the XLV by -21% and -13%, respectively.
---
Ownership Overview
4.04% Insiders
26.75% Mutual Funds
22.47% Other Institutional Investors
27.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DHR FAQ
What was Danaher Corp.’s price range in the past 12 months?
Danaher Corp. lowest stock price was $196.80 and its highest was $281.70 in the past 12 months.
What is Danaher Corp.’s market cap?
Danaher Corp.’s market cap is $151.80B.
When is Danaher Corp.’s upcoming earnings report date?
Danaher Corp.’s upcoming earnings report date is Apr 22, 2025 which is in 26 days.
How were Danaher Corp.’s earnings last quarter?
Danaher Corp. released its earnings results on Jan 29, 2025. The company reported $2.14 earnings per share for the quarter, missing the consensus estimate of $2.158 by -$0.018.
Is Danaher Corp. overvalued?
According to Wall Street analysts Danaher Corp.’s price is currently Undervalued.
Does Danaher Corp. pay dividends?
Danaher Corp. pays a Quarterly dividend of $0.319 which represents an annual dividend yield of 0.51%. See more information on Danaher Corp. dividends here
What is Danaher Corp.’s EPS estimate?
Danaher Corp.’s EPS estimate is 1.62.
How many shares outstanding does Danaher Corp. have?
Danaher Corp. has 714,709,840 shares outstanding.
What happened to Danaher Corp.’s price movement after its last earnings report?
Danaher Corp. reported an EPS of $2.14 in its last earnings report, missing expectations of $2.158. Following the earnings report the stock price went down -9.728%.
Which hedge fund is a major shareholder of Danaher Corp.?
Currently, no hedge funds are holding shares in DHR
---
Danaher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$264.50 (25.71% Upside)
$264.50 (25.71% Upside)
Blogger Sentiment
Bullish
DHR Sentiment 88%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 104.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.91%
12-Months-Change
Fundamentals
Return on Equity
7.57%
Trailing 12-Months
Asset Growth
-8.22%
Trailing 12-Months
Company Description
Danaher Corp.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
---
DHR Company Deck
---
DHR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong cash flow and innovation driving positive sentiment, but challenges in core revenue growth and specific segment declines, particularly in Diagnostics and the China market, created headwinds.Read More>---
DHR Revenue Breakdown
40.99% Diagnostics
30.70% Life Sciences
28.31% Biotechnology
---
DHR Stock 12 Month Forecast
Average Price Target
$264.50
▲(25.71% Upside)
Technical Analysis
Best Analysts Covering DHR
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+24.68%
upgraded a buy rating 5 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +24.68% per trade.
---